BiotechTube

Single FT1050 treated UCB unit

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin's Lymphoma (NHL)

Conditions

Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)

Trial Timeline

Jan 1, 2012 โ†’ Nov 1, 2013

NCT ID
NCT01527838

About Single FT1050 treated UCB unit

Single FT1050 treated UCB unit is a phase 1 stage product being developed by Fate Therapeutics for Non-Hodgkin's Lymphoma (NHL). The current trial status is completed. This product is registered under clinical trial identifier NCT01527838. Target conditions include Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL).

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01527838Phase 1Completed

Competing Products

20 competing products in Non-Hodgkin's Lymphoma (NHL)

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ๏ผ›YY-20394 + SHR1459 ๏ผ›YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
ABT-199 + KetoconazoleAbbViePhase 1
33
ABT-199 + RifampinAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + Rituximab + BendamustineAbbViePhase 1
33
ABBV-291AbbViePhase 1
33
ABT-199AbbViePhase 1
33
AvelumabMerckPhase 1
33

Other Products from Fate Therapeutics

ProHema-CB + Untreated CBPhase 2
44
ProTmune + Control ArmPhase 1/2
33
ProHema-CB TransplantPhase 1
25
FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludarabine + IL-2 + BendamustinePhase 1
25
FT596 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab + BendamustinePhase 1
25